Revance Therapeutics Receivables

Revance Therapeutics (RVNC) currently reports a receivables of $48M as of September 2024. That compares with $25M in the prior-year period — up 89.9% year over year. Use the charts on this page to explore Revance Therapeutics's receivables history and peer comparisons.

Revance Therapeutics's receivables increased from $25M to $48M — a 89.9% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Revance Therapeutics reported $48M in receivables as of September 2024. That compares with $25M in the prior-year period — up 89.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $48M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Revance Therapeutics, and consider following RVNC for alerts when major investors trade the stock.

Revance Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $48M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RVNC with unrelated industries.